Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Blood (2025) 146 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2025-5330

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

High-frequency monitoring of clonal dynamics in MPN using saliva and peripheral blood during interferon therapy

Eli Soyfer, Jianhong Heidmann, Xin (Helen) Huang, Valeria Rangel, Krista Tsai, Lucas Wadley, Brian Sworder, Nicholas Pannunzio, Angela Fleischman

Blood (2025) 146 (Supplement 1): 7268.

https://doi.org/10.1182/blood-2025-7268

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study

Alicia Palomino Mosquera, Hitomi Hosoya, Michael C. Jin, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Brian Sworder, Chih Long Liu, Elizabeth Spiteri, Yasodha Natkunam, James L Zehnder, Henning Stehr, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 10712–10713.

https://doi.org/10.1182/blood-2022-167900

Published: 2022

Journal Articles

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 8609–8610.

https://doi.org/10.1182/blood-2022-170087

Published: 2022

Journal Articles

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Blood (2022) 140 (Supplement 1): 7545–7547.

https://doi.org/10.1182/blood-2022-165600

Published: 2022

Journal Articles

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Navika D. Shukla, Joseph Schroers-Martin, Karan R. Kathuria, Brian Sworder, Stefan K. Alig, Matthew J Frank, David B. Miklos, Steven Coutre, Maximilian Diehn, Michael S. Khodadoust, Mark Roschewski, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 6403–6404.

https://doi.org/10.1182/blood-2022-165656

Published: 2022

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Blood (2022) 140 (Supplement 1): 1295–1296.

https://doi.org/10.1182/blood-2022-164744

Published: 2022

Journal Articles

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, Mia Carleton, Kailee L Tanaka, Brian Sworder, Vanna Hovanky, George E Duran, Tian Y. Zhang, Michael S. Khodadoust, David B. Miklos, Sally Arai, David Iberri, Michaela Liedtke, Surbhi Sidana, David M. Kurtz

Blood (2022) 140 (Supplement 1): 1546–1548.

https://doi.org/10.1182/blood-2022-160370

Published: 2022

Journal Articles

Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders

Blood (2022) 140 (Supplement 1): 172–174.

https://doi.org/10.1182/blood-2022-158647

Published: 2022

Journal Articles

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Mohammad Shahrokh Esfahani, Stefan Alig, Mahya Mehrmohamadi, Emily G. Hamilton, Daniel A King, Andre Schultz, Chloe B. Steen, Charles Macaulay, Brian Sworder, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 37.

https://doi.org/10.1182/blood-2021-150964

Published: 2021

Journal Articles

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Joseph G Schroers-Martin, Joanne Soo, Gabriel Brisou, Florian Scherer, David M. Kurtz, Brian Sworder, Michael S. Khodadoust, Michael C. Jin, Agnès Bru, Chih Long Liu, Henning Stehr, Paolo Vineis, Yasodha Natkunam, Lauren R Teras, Joo Y. Song, Bertrand Nadel, Maximilian Diehn, Sandrine Roulland, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 709.

https://doi.org/10.1182/blood-2021-151058

Published: 2021

Journal Articles

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Joseph G Schroers-Martin, MD, Joanne Soo, MD, Gabriel Brisou, MD, Florian Scherer, MD, David M. Kurtz, MDPhD, Brian Sworder, MD PhD, Michael S. Khodadoust, MD PhD, Michael C. Jin, BS, Agnès Bru, Chih Long Liu, PhD, Henning Stehr, PhD, Paolo Vineis, PhD, Yasodha Natkunam, MD PhD, Bertrand Nadel, PhD, Maximilian Diehn, MD PhD, Sandrine Roulland, PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142761

Published: 2020

Journal Articles

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Navika D Shukla, Alexander F. M. Craig, MPhil, Brian Sworder, MD PhD, David M. Kurtz, MDPhD, Charles Macaulay, MSc, BA, Andrea Garofalo, BS, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, George Duran, BA, Youn H. Kim, MD, James Zehnder, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD, Maximilian Diehn, MD PhD, Michael S. Khodadoust, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-141655

Published: 2020

Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139605

Published: 2020

Journal Articles

Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies

Andrea Garofalo, BS, BA, Joseph G Schroers-Martin, MD, Joanne Soo, MD, David M. Kurtz, MD PhD, Brian Sworder, MD PhD, Chih Long Liu, PhD, Benjamin A Pinsky, MD PhD, Helen Luikart, RN, MSN, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, Kiran Khush, MD, Maximilian Diehn, MD PhD, Arash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 885.

https://doi.org/10.1182/blood-2019-131602

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Chloe B. Steen, MSc, Bogdan A. Luca, PhD, Mohammad Shahrokh Esfahani, Barzin Y. Nabet, PhD, Brian Sworder, MD PhD, Farshad Farshidfar, MD PhD, Kiarash Shamardani, BA, David M. Kurtz, MD PhD, Chih Long Liu, PhD, Ranjana H Advani, MD, Yasodha Natkunam, MD PhD, June Helen Myklebust, PhD, Maximilian Diehn, MD PhD, Andrew Gentles, PhD, Aaron M Newman, PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 655.

https://doi.org/10.1182/blood-2019-129461

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

High-frequency monitoring of clonal dynamics in MPN using saliva and peripheral blood during interferon therapy

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis

Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only